Radiosonde apparatus

Accessories for radiofrequency generators, probes and cannula for the solutions to chronic spinal pain. (Item is on Manufacturer Allocation - Quantities may be Limited) (US Only) (Authorized Distributor Sub-Agreement Required - See Manufacturer

EPPENDORF(R) UVETTE 220 NM û 1 600 NM

BW5147.G.1.4.OUAR.1

General description Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. D -Camphor

Amino Acid Sequence Cys-Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Cys Application FR-1 is a cyclic RGDS peptide that acts via binding to FR-1 receptor, a 57 kDa Arg-Gly-Asp-Ser (RGDS)-binding protein involved in early embryogenesis.

Biochem/physiol Actions WZ4002 is an irreversible inhibitor of the gatekeeper EGFR-T790M mutation that binds to the active conformation of the EGFR kinase forming a covalent bond with Cys 797. WZ4002 is effective in the treatment of lung

Biochem/physiol Actions Originally characterized an ATP site-targeing kinase inhibitor (IC50 in nM = 2/VEGFR2, 15/SRC, 47/C-FMS, 851/GSK3, 9016/ERBB2, 9120/FGFR) with potent antiproliferation activity against cancer cultures (IC50 in nM =

Biochem/physiol Actions Originally characterized an ATP site-targeing kinase inhibitor (IC50 in nM = 2/VEGFR2, 15/SRC, 47/C-FMS, 851/GSK3, 9016/ERBB2, 9120/FGFR) with potent antiproliferation activity against cancer cultures (IC50 in nM =

Biochem/physiol Actions dBET1 is a JQ1-and-phthalimide conjugate that causes the degradation of BRD4 protein, a transcriptional coactivator that regulates the expression of genes that promote cancer cell proliferation and survival. JQ1 is a

Biochem/physiol Actions dBET1 is a JQ1-and-phthalimide conjugate that causes the degradation of BRD4 protein, a transcriptional coactivator that regulates the expression of genes that promote cancer cell proliferation and survival. JQ1 is a

Biochem/physiol Actions NIK SMI1 is an orally active, ATP site-targeting, potent and selective NF-&#954:B-inducing kinase inhibitor (h/m NIK IC50 = 230/395 pM: hKHS1/hPKD1/hLRRK2 = 49.6/75.

Biochem/physiol Actions NIK SMI1 is an orally active, ATP site-targeting, potent and selective NF-&#954:B-inducing kinase inhibitor (h/m NIK IC50 = 230/395 pM: hKHS1/hPKD1/hLRRK2 = 49.6/75.